02aa4891-0590-4a2f-bbd1-da2c88cc1508
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- MITOTIC_SPINDLE+0.300
- NOTCH_SIGNALING+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- ANDROGEN_RESPONSE+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- MYC_TARGETS_V1+0.200
Top 10 suppressed
- ESTROGEN_RESPONSE_LATE-0.300
- HYPOXIA-0.300
- MYOGENESIS-0.300
- ADIPOGENESIS-0.200
- APICAL_JUNCTION-0.200
- APICAL_SURFACE-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- COAGULATION-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d708a0d7-edda-46a8-b717-1b48c073c828 | — | — | 0.791 |
| 2 | TCGA-D8-A1Y0-01A-11R-A14M-07 | — | A | 0.780 |
| 3 | AUR-AFEA-TTM6-A-1-0-R-A741-41 | — | D | 0.766 |
| 4 | MDT-AP-3043 | Med | Medulloblastoma | 0.764 |
| 5 | SRR934919 | — | — | 0.731 |
| 6 | MDT-AP-3248 | Med | Medulloblastoma | 0.729 |
| 7 | SRR934808 | — | — | 0.729 |
| 8 | AUR-AE6Y-TTP1-A-1-0-R-A741-41 | — | D | 0.723 |
| 9 | TCGA-BL-A13I-01B-04R-A277-07 | — | — | 0.720 |
| 10 | E35A6AA5-331F-489B-8CE1-9D0BC4CDE119 | — | — | 0.714 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |